News Lilly falls on slower start for Foundayo versus Wegovy Sky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.
News Sun sets out $11.75bn takeover play for Organon After downplaying persistent rumours for months, Sun Pharma has broken cover with an $11.75 billion takeover agreement for Organon.
News FDA declines to approve AbbVie's Botox follow-up AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.
News FDA clears first genetic hearing loss gene therapy Regeneron's Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.
News Ray's upscaled Series B, and other biofinancings This week's crop of private financings includes nine-figure rounds for Ray Therapeutics and Tortugas, with Serif and Alloy also in on the action.
News Novo says oral semaglutide works in diabetic kids Novo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year.
News NHS use of Incyte's anal cancer drug Zynyz backed by NICE Hundreds of patients in England and Wales with anal cancer could soon be eligible for treatment with Incyte's cancer immunotherapy Zynyz.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.